Highlights
MILFORD, Mass., Aug. 2, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the second quarter of 2023.
Sales for the second quarter of 2023 were $741 million, an increase of 4% as reported, compared to sales of $714 million for the second quarter of 2022. Currency translation decreased sales by 1%, while the impact of acquisitions increased sales by 2%, resulting in organic constant currency sales growth of 3%.
On a GAAP basis, diluted earnings per share (EPS) for the second quarter of 2023 was $2.55, compared to $2.72 for the second quarter of 2022. On a non-GAAP basis, EPS was $2.80, compared to $2.75 for the second quarter of 2022.
"I want to thank all of our teams for their dedication and focus on commercial execution and innovation, delivering game-changing new products like Xevo TQ Absolute and Alliance iS to address our customers' unmet needs," said Dr. Udit Batra, President & CEO, Waters Corporation. "We saw solid growth across the U.S. and Europe, while navigating a difficult market in China. We executed well across our end-markets with mass spec growth of almost 20%, and TA continued its trend of double-digit growth."
Dr. Batra continued, "I am confident that our commercial execution, revitalized portfolio, and continued investment in our high growth adjacencies position us well for future growth. We are also off to a great start with the acquisition of Wyatt, which contributed 2% growth in the quarter."
Second Quarter 2023
During the second quarter of 2023, sales into the pharmaceutical market decreased 2% as reported and 4% in organic constant currency, sales into the industrial market increased 10% as reported and 11% in organic constant currency and sales into the academic and government markets increased 23% as reported and 21% in organic constant currency.
During the quarter, instrument system sales increased 1% as reported and decreased 2% in organic constant currency, while recurring revenues, which represent the combination of service and precision chemistries, increased 6% as reported and 7% in organic constant currency.
Geographically, sales in Asia during the quarter decreased 8% as reported and 5% in organic constant currency (with China sales declining high teens). Sales in the Americas increased 10% as reported and 7% in organic constant currency (with U.S. sales growing 12% as reported and 8% in organic constant currency). Sales in Europe increased 13% as reported and 9% in organic constant currency.
First Half 2023
Sales for the first half of 2023 were $1,425 million, an increase of 1% as reported, compared to sales of $1,405 million for the first half of 2022. Currency translation decreased sales by 3%, while the impact of acquisitions increased sales by 1%, resulting in first half 2023 organic constant currency sales growth of 3%.
On a GAAP basis, EPS for the first half of 2023 was $4.95, compared to $5.35 for the first half of 2022. On a non-GAAP basis, EPS was $5.31, compared to $5.55 in the first half of 2022. This includes a headwind of approximately 4% due to unfavorable foreign exchange.
For the first half of 2023, sales into the pharmaceutical market decreased 5% as reported and 4% in organic constant currency, sales into the industrial market increased 5% as reported and 7% in organic constant currency and sales into the academic and government markets increased 30% as reported and 33% in organic constant currency.
For the first half of 2023, instrument system sales decreased 3% as reported and in organic constant currency, while recurring revenues increased 5% as reported and 7% in organic constant currency.
Geographically, sales in Asia for the first half of 2023 decreased 5% as reported and were flat in organic constant currency. Sales in the Americas increased 5% as reported and 3% in organic constant currency (with U.S. sales growing 4% as reported and 2% in organic constant currency). Sales in Europe increased 6% as reported and in organic constant currency.
Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website www.waters.com in the Investor Relations section.
Full-Year and Third Quarter 2023 Financial Guidance
Full-Year 2023 Financial Guidance
The Company now expects full-year 2023 organic constant currency sales growth in the range of 0.5% to 1.5%. Currency translation is expected to have minimal impact on full-year organic sales growth. The Wyatt transaction is expected to increase full-year reported sales growth by approximately 2.5%. The resulting full-year 2023 reported sales growth is expected in the range of 3% to 4%.
The Company is updating its full-year 2023 non-GAAP EPS guidance to now be in the range of $12.20 to $12.30, which includes an estimated headwind of approximately 1% due to unfavorable foreign exchange.
Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year.
Third Quarter 2023 Financial Guidance
The Company expects third quarter 2023 organic constant currency sales growth to decline in the range of -4% to -2%. Currency translation is expected to increase third quarter sales growth by approximately 1%. The Wyatt transaction is expected to increase third quarter reported sales growth by approximately 4%. The resulting third quarter 2023 reported sales growth is expected in the range of 1% to 3%.
The Company expects third quarter 2023 non-GAAP EPS in the range of $2.50 to $2.60, which includes a neutral foreign exchange impact.
Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the third quarter.
Conference Call Details
Waters Corporation will webcast its second quarter 2023 financial results conference call today, August 2, 2023, at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select "Investors" under the "About Waters" section, navigate to "Events & Presentations," and click on the "Webcast." A replay will be available through August 16, 2023 on the same website by webcast and also by phone at (866) 363-1807.
About Waters Corporation
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 8,000 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.
Non-GAAP Financial Measures
This press release contains financial measures, such as organic constant currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per diluted share and adjusted free cash flow, among others, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.
Cautionary Statement
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks related to, expectations or ability to realize commercial success subsequent to the completion of the Wyatt transaction; the impact of this transaction on the Company's business, anticipated progress on Waters' research programs, development of new analytical instruments and associated software or consumables, manufacturing development and capabilities; the increased indebtedness of the Company as a result of the Wyatt transaction, the repayment of which could impact the Company's future results, market prospects for its products and sales and earnings guidance; foreign currency exchange rate fluctuations potentially affecting translation of the Company's future non-U.S. operating results, particularly when a foreign currency weakens against the U.S. dollar; current global economic, sovereign and political conditions and uncertainties, including the effect of new or proposed tariff or trade regulations; changes in inflation and interest rates; the impacts and costs of war, in particular as a result of the ongoing conflict between Russia and Ukraine; and the possibility of further escalation resulting in new geopolitical and regulatory instability; the United Kingdom's exit from the European Union and the Chinese government's ongoing tightening of restrictions on procurement by government-funded customers; the Company's ability to access capital, maintain liquidity and service the Company's debt in volatile market conditions; risks related to the effects of the ongoing COVID-19 pandemic on our business, financial condition, results of operations and prospects; changes in timing and demand for the Company's products among the Company's customers and various market sectors, particularly as a result of fluctuations in their expenditures or ability to obtain funding; the ability to realize the expected benefits related to the Company's various cost-saving initiatives; the introduction of competing products by other companies and loss of market share, as well as pressures on prices from competitors and/or customers; changes in the competitive landscape as a result of changes in ownership, mergers and continued consolidation among the Company's competitors; regulatory, economic and competitive obstacles to new product introductions; lack of acceptance of new products and inability to grow organically through innovation; rapidly changing technology and product obsolescence; risks associated with previous or future acquisitions, strategic investments, joint ventures and divestitures, including risks associated with contingent purchase price payments and expansion of our business into or developing markets; risks associated with unexpected disruptions in operations; failure to adequately protect the Company's intellectual property, infringement of intellectual property rights of third parties and inability to obtain licenses on commercially reasonable terms; the Company's ability to acquire adequate sources of supply and its reliance on outside contractors for certain components and modules, as well as disruptions to its supply chain; risks associated with third-party sales intermediaries and resellers; the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates as well as shifts in taxable income among jurisdictions with different effective tax rates, the outcome of ongoing and future tax examinations and changes in legislation affecting the Company's effective tax rate; the Company's ability to attract and retain qualified employees and management personnel; risks associated with cybersecurity and technology, including attempts by third parties to defeat the security measures of the Company and its third-party partners; increased regulatory burdens as the Company's business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others, and in connection with government contracts; regulatory, environmental, and logistical obstacles affecting the distribution of the Company's products, completion of purchase order documentation and the ability of customers to obtain letters of credit or other financing alternatives; risks associated with litigation and other legal and regulatory proceedings; and the impact and costs incurred from changes in accounting principles and practices. Such factors and others are discussed more fully in the sections entitled "Forward-Looking Statements" and "Risk Factors" of the Company's annual report on Form 10-K for the year ended December 31, 2022, as well as in the sections entitled "Special Note Regarding Forward-Looking Statements" and "Risk Factors" of the Company's quarterly report on Form 10-Q for the quarterly period ended April 1, 2023, as filed with the Securities and Exchange Commission ("SEC"), which discussions are incorporated by reference in this release, as updated by the Company's future filings with the SEC. The forward-looking statements included in this release represent the Company's estimates or views as of the date of this release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.
Waters Corporation and Subsidiaries | |||||||
Consolidated Statements of Operations | |||||||
(In thousands, except per share data) | |||||||
(Unaudited) | |||||||
Three Months Ended | Six Months Ended | ||||||
July 1, 2023 | July 2, 2022 | July 1, 2023 | July 2, 2022 | ||||
Net sales | $ 740,576 | $ 714,319 | $ 1,425,250 | $ 1,404,891 | |||
Costs and operating expenses: | |||||||
Cost of sales | 301,076 | 307,206 | 585,456 | 592,891 | |||
Selling and administrative expenses | 186,953 | 161,877 | 368,909 | 319,352 | |||
Research and development expenses | 45,873 | 44,006 | 88,564 | 84,478 | |||
Purchased intangibles amortization | 6,815 | 1,598 | 8,294 | 3,271 | |||
Acquired in-process research and development | - | - | - | 9,797 | |||
Operating income | 199,859 | 199,632 | 374,027 | 395,102 | |||
Other (expense) income, net | (352) | 1,535 | 1,036 | 1,705 | |||
Interest expense, net | (19,232) | (8,893) | (29,615) | (17,838) | |||
Income from operations before income taxes | 180,275 | 192,274 | 345,448 | 378,969 | |||
Provision for income taxes | 29,721 | 27,410 | 53,971 | 54,274 | |||
Net income | $ 150,554 | $ 164,864 | $ 291,477 | $ 324,695 | |||
Net income per basic common share | $ 2.56 | $ 2.74 | $ 4.97 | $ 5.38 | |||
Weighted-average number of basic common shares | 58,857 | 60,206 | 58,703 | 60,399 | |||
Net income per diluted common share | $ 2.55 | $ 2.72 | $ 4.95 | $ 5.35 | |||
Weighted-average number of diluted common shares and equivalents | 59,010 | 60,510 | 58,909 | 60,744 | |||
Waters Corporation and Subsidiaries | |||||||||||||||||
Reconciliation of GAAP to Adjusted Non-GAAP | |||||||||||||||||
Net Sales by Operating Segments, Products & Services, Geography and Markets | |||||||||||||||||
Three Months Ended July 1, 2023 and July 2, 2022 | |||||||||||||||||
(In thousands) | |||||||||||||||||
Organic | |||||||||||||||||
Constant | |||||||||||||||||
Three Months Ended | Percent | Impact of | Impact of | Currency | |||||||||||||
July 1, 2023 | July 2, 2022 | Change | Currency | Acquisitions | Growth Rate (a) | ||||||||||||
NET SALES - OPERATING SEGMENTS | |||||||||||||||||
Waters | $ | 653,235 | $ | 635,152 | 3 % | (1 %) | 2 % | 2 % | |||||||||
TA | 87,341 | 79,167 | 10 % | (1 %) | 0 % | 11 % | |||||||||||
Total | $ | 740,576 | $ | 714,319 | 4 % | (1 %) | 2 % | 3 % | |||||||||
NET SALES - PRODUCTS & SERVICES | |||||||||||||||||
Instruments | $ | 342,007 | $ | 337,683 | 1 % | (1 %) | 4 % | (2 %) | |||||||||
Service | 262,650 | 244,689 | 7 % | (2 %) | 1 % | 8 % | |||||||||||
Chemistry | 135,919 | 131,947 | 3 % | (2 %) | 0 % | 5 % | |||||||||||
Total Recurring | 398,569 | 376,636 | 6 % | (2 %) | 1 % | 7 % | |||||||||||
Total | $ | 740,576 | $ | 714,319 | 4 % | (1 %) | 2 % | 3 % | |||||||||
NET SALES - GEOGRAPHY | |||||||||||||||||
Asia | $ | 254,623 | $ | 278,010 | (8 %) | (3 %) | 0 % | (5 %) | |||||||||
Americas | 282,927 | 257,271 | 10 % | 0 % | 3 % | 7 % | |||||||||||
Europe | 203,026 | 179,038 | 13 % | 1 % | 3 % | 9 % | |||||||||||
Total | $ | 740,576 | $ | 714,319 | 4 % | (1 %) | 2 % | 3 % | |||||||||
NET SALES - MARKETS | |||||||||||||||||
Pharmaceutical | $ | 426,744 | $ | 437,171 | (2 %) | (1 %) | 3 % | (4 %) | |||||||||
Industrial | 229,655 | 208,517 | 10 % | (1 %) | 0 % | 11 % | |||||||||||
Academic & Government | 84,177 | 68,631 | 23 % | (1 %) | 3 % | 21 % | |||||||||||
Total | $ | 740,576 | $ | 714,319 | 4 % | (1 %) | 2 % | 3 % | |||||||||
(a) | The Company believes that referring to comparable organic constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Organic constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. See description of non-GAAP financial measures contained in this release. | ||||||||||||||||
Waters Corporation and Subsidiaries | |||||||||||||||||
Reconciliation of GAAP to Adjusted Non-GAAP | |||||||||||||||||
Net Sales by Operating Segments, Products & Services, Geography and Markets | |||||||||||||||||
Six Months Ended July 1, 2023 and July 2, 2022 | |||||||||||||||||
(In thousands) | |||||||||||||||||
Organic | |||||||||||||||||
Constant | |||||||||||||||||
Six Months Ended | Percent | Impact of | Impact of | Currency | |||||||||||||
July 1, 2023 | July 2, 2022 | Change | Currency | Acquisitions | Growth Rate (a) | ||||||||||||
NET SALES - OPERATING SEGMENTS | |||||||||||||||||
Waters | $ | 1,255,310 | $ | 1,248,308 | 1 % | (2 %) | 1 % | 2 % | |||||||||
TA | 169,940 | 156,583 | 9 % | (1 %) | 0 % | 10 % | |||||||||||
Total | $ | 1,425,250 | $ | 1,404,891 | 1 % | (3 %) | 1 % | 3 % | |||||||||
NET SALES - PRODUCTS & SERVICES | |||||||||||||||||
Instruments | $ | 644,949 | $ | 662,905 | (3 %) | (2 %) | 2 % | (3 %) | |||||||||
Service | 510,867 | 484,421 | 5 % | (3 %) | 0 % | 8 % | |||||||||||
Chemistry | 269,434 | 257,565 | 5 % | (2 %) | 0 % | 7 % | |||||||||||
Total Recurring | 780,301 | 741,986 | 5 % | (3 %) | 1 % | 7 % | |||||||||||
Total | $ | 1,425,250 | $ | 1,404,891 | 1 % | (3 %) | 1 % | 3 % | |||||||||
NET SALES - GEOGRAPHY | |||||||||||||||||
Asia | $ | 507,704 | $ | 532,344 | (5 %) | (5 %) | 0 % | 0 % | |||||||||
Americas | 529,348 | 506,108 | 5 % | 0 % | 2 % | 3 % | |||||||||||
Europe | 388,198 | 366,439 | 6 % | (2 %) | 2 % | 6 % | |||||||||||
Total | $ | 1,425,250 | $ | 1,404,891 | 1 % | (3 %) | 1 % | 3 % | |||||||||
NET SALES - MARKETS | |||||||||||||||||
Pharmaceutical | $ | 811,642 | $ | 852,943 | (5 %) | (3 %) | 2 % | (4 %) | |||||||||
Industrial | 439,305 | 417,914 | 5 % | (2 %) | 0 % | 7 % | |||||||||||
Academic & Government | 174,303 | 134,034 | 30 % | (4 %) | 1 % | 33 % | |||||||||||
Total | $ | 1,425,250 | $ | 1,404,891 | 1 % | (3 %) | 1 % | 3 % | |||||||||
(a) | The Company believes that referring to comparable organic constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Organic constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. See description of non-GAAP financial measures contained in this release. | ||||||||||||||||
Waters Corporation and Subsidiaries | |||||||||||||||||||||||||||||
Reconciliation of GAAP to Adjusted Non-GAAP Financials | |||||||||||||||||||||||||||||
Three and Six Months Ended July 1, 2023 and July 2, 2022 | |||||||||||||||||||||||||||||
(In thousands, except per share data) | |||||||||||||||||||||||||||||
Acquired | Income from | ||||||||||||||||||||||||||||
IPR&D and | Operations | ||||||||||||||||||||||||||||
Selling & | Research & | Operating | Other | before | Provision for | Diluted | |||||||||||||||||||||||
Administrative | Development | Operating | Income | Income | Income | Income | Net | Earnings | |||||||||||||||||||||
Expenses(a) | Expenses | Income | Percentage | (Expense) | Taxes | Taxes | Income | per Share | |||||||||||||||||||||
Three Months Ended July 1, 2023 | |||||||||||||||||||||||||||||
GAAP | $ | 193,768 | $ | 45,873 | $ | 199,859 | 27.0 % | $ | (352) | $ | 180,275 | $ | 29,721 | $ | 150,554 | $ | 2.55 | ||||||||||||
Adjustments: | |||||||||||||||||||||||||||||
Purchased intangibles amortization (b) | (6,815) | - | 6,815 | 0.9 % | - | 6,815 | 1,616 | 5,199 | 0.09 | ||||||||||||||||||||
Restructuring costs and certain other items (d) | (5,229) | - | 5,229 | 0.7 % | - | 5,229 | 1,217 | 4,012 | 0.07 | ||||||||||||||||||||
Acquisition related costs (e) | (3,693) | - | 3,693 | 0.5 % | - | 3,693 | 886 | 2,807 | 0.05 | ||||||||||||||||||||
Retention bonus obligation (g) | (2,643) | (881) | 3,524 | 0.5 % | - | 3,524 | 846 | 2,678 | 0.05 | ||||||||||||||||||||
Adjusted Non-GAAP | $ | 175,388 | $ | 44,992 | $ | 219,120 | 29.6 % | $ | (352) | $ | 199,536 | $ | 34,286 | $ | 165,250 | $ | 2.80 | ||||||||||||
Three Months Ended July 2, 2022 | |||||||||||||||||||||||||||||
GAAP | $ | 163,475 | $ | 44,006 | $ | 199,632 | 27.9 % | $ | 1,535 | $ | 192,274 | $ | 27,410 | $ | 164,864 | $ | 2.72 | ||||||||||||
Adjustments: | |||||||||||||||||||||||||||||
Purchased intangibles amortization (b) | (1,598) | - | 1,598 | 0.2 % | - | 1,598 | 366 | 1,232 | 0.02 | ||||||||||||||||||||
Restructuring costs and certain other items (d) | (1,830) | - | 1,830 | 0.3 % | (1,818) | 12 | (5) | 17 | - | ||||||||||||||||||||
Certain income tax items (f) | - | - | - | - | - | - | (506) | 506 | 0.01 | ||||||||||||||||||||
Adjusted Non-GAAP | $ | 160,047 | $ | 44,006 | $ | 203,060 | 28.4 % | $ | (283) | $ | 193,884 | $ | 27,265 | $ | 166,619 | $ | 2.75 | ||||||||||||
Six Months Ended July 1, 2023 | |||||||||||||||||||||||||||||
GAAP | $ | 377,203 | $ | 88,564 | $ | 374,027 | 26.2 % | $ | 1,036 | $ | 345,448 | $ | 53,971 | $ | 291,477 | $ | 4.95 | ||||||||||||
Adjustments: | |||||||||||||||||||||||||||||
Purchased intangibles amortization (b) | (8,294) | - | 8,294 | 0.6 % | - | 8,294 | 1,951 | 6,343 | 0.11 | ||||||||||||||||||||
Restructuring costs and certain other items (d) | (4,824) | - | 4,824 | 0.3 % | - | 4,824 | 1,473 | 3,351 | 0.06 | ||||||||||||||||||||
Acquisition related costs (e) | (12,035) | - | 12,035 | 0.8 % | - | 12,035 | 2,888 | 9,147 | 0.16 | ||||||||||||||||||||
Retention bonus obligation (g) | (2,643) | (881) | 3,524 | 0.2 % | - | 3,524 | 846 | 2,678 | 0.05 | ||||||||||||||||||||
Adjusted Non-GAAP | $ | 349,407 | $ | 87,683 | $ | 402,704 | 28.3 % | $ | 1,036 | $ | 374,125 | $ | 61,129 | $ | 312,996 | $ | 5.31 | ||||||||||||
Six Months Ended July 2, 2022 | |||||||||||||||||||||||||||||
GAAP | $ | 322,623 | $ | 94,275 | $ | 395,102 | 28.1 % | $ | 1,705 | $ | 378,969 | $ | 54,274 | $ | 324,695 | $ | 5.35 | ||||||||||||
Adjustments: | |||||||||||||||||||||||||||||
Purchased intangibles amortization (b) | (3,271) | - | 3,271 | 0.2 % | - | 3,271 | 749 | 2,522 | 0.04 | ||||||||||||||||||||
Acquired in-process research and development (c) | - | (9,797) | 9,797 | 0.7 % | - | 9,797 | 2,351 | 7,446 | 0.12 | ||||||||||||||||||||
Restucturing costs and certain other items (d) | (4,205) | - | 4,205 | 0.3 % | (2,234) | 1,971 | 456 | 1,515 | 0.02 | ||||||||||||||||||||
Certain income tax items (f) | - | - | - | - | - | - | (994) | 994 | 0.02 | ||||||||||||||||||||
Adjusted Non-GAAP | $ | 315,147 | $ | 84,478 | $ | 412,375 | 29.4 % | $ | (529) | $ | 394,008 | $ | 56,836 | $ | 337,172 | $ | 5.55 | ||||||||||||
(a) | Selling & administrative expenses include purchased intangibles amortization. | ||||||||||||||||||||||||||||
(b) | The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time. | ||||||||||||||||||||||||||||
(c) | Acquired in-process research and development was excluded as it relates to the cost of a licensing arrangement for charge detection mass spectrometry that the Company believes is unusual and not indicative of its normal business operations. | ||||||||||||||||||||||||||||
(d) | Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company. | ||||||||||||||||||||||||||||
(e) | Acquisition related costs include all incremental expenses incurred, such as advisory, legal, accounting, tax, valuation, and other professional fees. The Company believes that these costs are not normal and do not represent future ongoing business expenses. | ||||||||||||||||||||||||||||
(f) | Certain income tax items were excluded as these non-cash expenses and benefits represent updates in management's assessment of ongoing examinations or other tax items that are not indicative of the Company's normal or future income tax expense. | ||||||||||||||||||||||||||||
(g) | In connection with the Wyatt acquisition, the Company started to recognize a two-year retention bonus obligation that is contingent upon the employee's providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses. | ||||||||||||||||||||||||||||
Waters Corporation and Subsidiaries | |||||||
Preliminary Condensed Unclassified Consolidated Balance Sheets | |||||||
(In thousands and unaudited) | |||||||
July 1, 2023 | December 31, 2022 | ||||||
Cash, cash equivalents and investments | $ 330,578 | $ 481,391 | |||||
Accounts receivable | 693,436 | 722,892 | |||||
Inventories | 536,828 | 455,710 | |||||
Property, plant and equipment, net | 615,211 | 582,217 | |||||
Intangible assets, net | 649,731 | 227,399 | |||||
Goodwill | 1,313,501 | 430,328 | |||||
Other assets | 408,911 | 381,516 | |||||
Total assets | $ 4,548,196 | $ 3,281,453 | |||||
Notes payable and debt | $ 2,630,198 | $ 1,574,878 | |||||
Other liabilities | 1,146,769 | 1,202,087 | |||||
Total liabilities | 3,776,967 | 2,776,965 | |||||
Total stockholders' equity | 771,229 | 504,488 | |||||
Total liabilities and stockholders' equity | $ 4,548,196 | $ 3,281,453 | |||||
Waters Corporation and Subsidiaries | |||||||||||
Preliminary Condensed Consolidated Statements of Cash Flows | |||||||||||
Three and Six Months Ended July 1, 2023 and July 2, 2022 | |||||||||||
(In thousands and unaudited) | |||||||||||
Three Months Ended | Six Months Ended | ||||||||||
July 1, 2023 | July 2, 2022 | July 1, 2023 | July 2, 2022 | ||||||||
Cash flows from operating activities: | |||||||||||
Net income | $ 150,554 | $ 164,864 | $ 291,477 | $ 324,695 | |||||||
Adjustments to reconcile net income to net | |||||||||||
cash provided by operating activities: | |||||||||||
Stock-based compensation | 10,929 | 9,789 | 23,734 | 20,722 | |||||||
Depreciation and amortization | 38,884 | 34,227 | 70,038 | 66,891 | |||||||
Change in operating assets and liabilities and other, net | (182,249) | (151,977) | (170,380) | (157,445) | |||||||
Net cash provided by operating activities | 18,118 | 56,903 | 214,869 | 254,863 | |||||||
Cash flows from investing activities: | |||||||||||
Additions to property, plant, equipment | |||||||||||
and software capitalization | (46,607) | (46,995) | (80,997) | (74,746) | |||||||
Business acquisitions, net of cash acquired | (1,285,907) | - | (1,285,907) | - | |||||||
(Investments in) proceeds from equity investments, net | - | (1,139) | - | 5,646 | |||||||
Payments for intellectual property licenses | - | - | - | (4,897) | |||||||
Net change in investments | - | 21,739 | (16) | 66,594 | |||||||
Net cash used in investing activities | (1,332,514) | (26,395) | (1,366,920) | (7,403) | |||||||
Cash flows from financing activities: | |||||||||||
Net change in debt | 1,149,742 | 40,000 | 1,054,782 | (30,000) | |||||||
Proceeds from stock plans | 6,250 | 18,082 | 8,628 | 30,914 | |||||||
Purchases of treasury shares | (236) | (151,808) | (69,741) | (321,944) | |||||||
Other cash flow from financing activities, net | 2,418 | 10,956 | 5,294 | 10,849 | |||||||
Net cash provided by (used in) financing activities | 1,158,174 | (82,770) | 998,963 | (310,181) | |||||||
Effect of exchange rate changes on cash and cash equivalents | (155) | (8,911) | 2,252 | (19,616) | |||||||
Decrease in cash and cash equivalents | (156,377) | (61,173) | (150,836) | (82,337) | |||||||
Cash and cash equivalents at beginning of period | 486,070 | 480,070 | 480,529 | 501,234 | |||||||
Cash and cash equivalents at end of period | $ 329,693 | $ 418,897 | $ 329,693 | $ 418,897 | |||||||
Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a) | |||||||||||
Net cash provided by operating activities - GAAP | $ 18,118 | $ 56,903 | $ 214,869 | $ 254,863 | |||||||
Adjustments: | |||||||||||
Additions to property, plant, equipment | |||||||||||
and software capitalization | (46,607) | (46,995) | (80,997) | (74,746) | |||||||
Tax reform payments | 72,101 | 38,454 | 72,101 | 38,454 | |||||||
Litigation settlements paid, net | (375) | - | (750) | (584) | |||||||
Major facility renovations | 4,394 | 11,112 | 8,860 | 17,039 | |||||||
Payment of acquired Wyatt liabilities (b) | 25,617 | - | 25,617 | - | |||||||
Free Cash Flow - Adjusted Non-GAAP | $ 73,248 | $ 59,474 | $ 239,700 | $ 235,026 | |||||||
(a) | The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies. | ||||||||||
(b) | In connection with the Wyatt acquisition, the Company assumed certain obligations of Wyatt and paid those obligations immediately upon closing the transaction. The Company believes that the assumed obligations do not represent future ongoing business expenses. | ||||||||||
Waters Corporation and Subsidiaries | |||||||||||
Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook | |||||||||||
Three Months Ended | Twelve Months Ended | ||||||||||
September 30, 2023 | December 31, 2023 | ||||||||||
Range | Range | ||||||||||
Projected Sales | |||||||||||
Organic constant currency sales growth rate (a) | (4.0 %) | - | (2.0 %) | 0.5 % | - | 1.5 % | |||||
Impact of: | |||||||||||
Currency translation | 1.0 % | - | 1.0 % | - | - | - | |||||
Acquisitions | 4.0 % | - | 4.0 % | 2.5 % | - | 2.5 % | |||||
Sales growth rate as reported | 1.0 % | - | 3.0 % | 3.0 % | - | 4.0 % | |||||
Range | Range | ||||||||||
Projected Earnings Per Diluted Share | |||||||||||
GAAP earnings per diluted share | $ 1.84 | - | $ 1.94 | $ 10.92 | - | $ 11.02 | |||||
Adjustments: | |||||||||||
Purchased intangibles amortization | $ 0.16 | - | $ 0.16 | $ 0.42 | - | $ 0.42 | |||||
Restructuring costs and certain other items | $ 0.40 | - | $ 0.40 | $ 0.47 | - | $ 0.47 | |||||
Acquisition related costs | $ - | - | $ - | $ 0.15 | - | $ 0.15 | |||||
Retention bonus obligation | $ 0.10 | - | $ 0.10 | $ 0.24 | - | $ 0.24 | |||||
Adjusted non-GAAP earnings per diluted share | $ 2.50 | - | $ 2.60 | $ 12.20 | - | $ 12.30 | |||||
(a) Organic constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results. | |||||||||||
These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance. | |||||||||||
Contact: Caspar Tudor, Head of Investor Relations – (508) 482-2429
| Last Trade: | US$368.16 |
| Daily Change: | 7.53 2.09 |
| Daily Volume: | 1,302,652 |
| Market Cap: | US$21.860B |
November 07, 2024 November 01, 2024 October 10, 2024 October 08, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
